期刊
BIOTECHNOLOGY AND BIOENGINEERING
卷 116, 期 10, 页码 2778-2796出版社
WILEY
DOI: 10.1002/bit.27101
关键词
cell engineering; Chinese hamster ovary; CRISPR; expression system; posttranslational modification
资金
- Novo Nordisk Foundation [NNF10CC1016517]
- H2020 Marie Sklodowska-Curie Actions [642663]
- Osterreichische Forschungsforderungsgesellschaft
- Marie Curie Actions (MSCA) [642663] Funding Source: Marie Curie Actions (MSCA)
The number of approved biopharmaceuticals, where product quality attributes remain of major importance, is increasing steadily. Within the available variety of expression hosts, the production of biopharmaceuticals faces diverse limitations with respect to posttranslational modifications (PTM), while different biopharmaceuticals demand different forms and specifications of PTMs for proper functionality. With the growing toolbox of genetic engineering technologies, it is now possible to address general as well as host- or biopharmaceutical-specific product quality obstacles. In this review, we present diverse expression systems derived from mammalians, bacteria, yeast, plants, and insects as well as available genetic engineering tools. We focus on genes for knockout/knockdown and overexpression for meaningful approaches to improve biopharmaceutical PTMs and discuss their applicability as well as future trends in the field.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据